Radius Health Inc (NASDAQ:RDUS) – Analysts at SVB Leerink decreased their FY2024 earnings per share (EPS) estimates for Radius Health in a research report issued on Thursday, July 23rd. SVB Leerink analyst B. Canino now anticipates that the biopharmaceutical company will post earnings of $1.39 per share for the year, down from their previous estimate of $1.57. SVB Leerink currently has a “Market Perform” rating and a $18.00 target price on the stock.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.09). The business had revenue of $47.92 million during the quarter, compared to the consensus estimate of $46.77 million.
Radius Health stock opened at $13.30 on Monday. The stock has a 50-day moving average of $13.53 and a two-hundred day moving average of $15.48. Radius Health has a one year low of $10.32 and a one year high of $29.97. The stock has a market cap of $636.01 million, a PE ratio of -4.80 and a beta of 1.19.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Valeo Financial Advisors LLC purchased a new position in shares of Radius Health in the first quarter valued at approximately $32,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Radius Health by 51.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 1,260 shares during the period. Advisor Group Holdings Inc. acquired a new stake in Radius Health in the first quarter valued at approximately $48,000. Great West Life Assurance Co. Can acquired a new stake in Radius Health in the fourth quarter valued at approximately $50,000. Finally, Meeder Asset Management Inc. raised its holdings in Radius Health by 1,127.1% in the first quarter. Meeder Asset Management Inc. now owns 5,350 shares of the biopharmaceutical company’s stock valued at $69,000 after acquiring an additional 4,914 shares in the last quarter.
In other news, major shareholder Target N. V. Biotech acquired 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The stock was purchased at an average cost of $13.21 per share, for a total transaction of $330,250.00. Following the completion of the transaction, the insider now owns 6,956,685 shares in the company, valued at $91,897,808.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Target N. V. Biotech bought 50,000 shares of the stock in a transaction on Thursday, April 30th. The shares were bought at an average cost of $15.75 per share, with a total value of $787,500.00. The disclosure for this purchase can be found here. 2.92% of the stock is owned by corporate insiders.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.